Dementia With Lewy Bodies Clinical Trial
Official title:
PERSEVERE in Lewy Body Dementia: A Randomized, Controlled Trial of Peer Mentor Support and Caregiver Education
Lewy Body Dementia (LBD) is the second most common form of degenerative dementia, affecting at least 2.4 million US adults, and the overwhelming majority of persons living with LBD (PLBD) are cared for by family caregivers. LBD caregiver strain: 1) exceeds that of non-LBD dementia caregivers; 2) worsens caregiver physical and mental health; and 3) increases the risk of PLBD hospitalization and institutionalization. LBD progression is complicated by combined motor, cognitive, and neuropsychiatric decline, and is punctuated by falls, infections, dehydration, and neuropsychiatric symptoms leading to acute healthcare utilization. Although family caregivers are uniquely positioned to identify and manage these challenges, which may avert emergency department visits and reduce morbidity, many caregivers lack the knowledge, skills, confidence, resources, and support to do so. The study team aims to 1) quantify the impact of PERSEVERE on caregiver knowledge, attitudes, mastery, and strain; 2) identify the intervention and mentor factors determining implementation fidelity; and 3) test the effects of PERSEVERE on PLBD quality of life and healthcare utilization. This will be accomplished in an NIH Behavioral Model Stage II national, randomized, attention-controlled, 12-week trial of PERSEVERE in 502 LBD caregivers in partnership with the Lewy Body Dementia Association, Parkinson's Foundation, and LBD Caregiver Advisors. The study team will match intervention arm caregivers with a trained peer mentor who will coach them through a modular, theory-based curriculum on LBD knowledge and social support. Attention-control participants will receive weekly, curated links to educational materials. The study team will identify immediate and delayed intervention effects, including mediators of strain at 12 weeks, and caregiver strain and PLBD outcomes at nine months. Implementation fidelity and PLBD healthcare utilization will be tracked biweekly. Qualitative methods will explore the intervention- and mentor-specific factors predicting fidelity, mentee outcomes, and retention. Remote recruitment, mentoring, and community engagement strategies will maximize accessibility and inclusion of underrepresented caregiver groups. Results will illuminate the extent to which leveraging prior LBD caregivers as expert interventionists can improve current caregiver outcomes, and in turn, PLBD outcomes. These results will inform future adaptation and dissemination of this model for other conditions.
Status | Recruiting |
Enrollment | 622 |
Est. completion date | June 30, 2028 |
Est. primary completion date | October 15, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Peer Mentors 1. Participants must be 18 years of age or older. 2. participant must be English-speaking. 3. Participant must be US-dwelling. 4. Participants must be either: 1. Individuals currently cohabitating with or spending at least 10 hours weekly on caregiving for a family member diagnosed with LBD, as measured by LBCRS score = 3, OR 2. met this criterion in the past if the family member with LBD is deceased. 5. Each participant must have access to and comfort with telephone use, including adequate hearing or appropriate assistive devices to communicate by phone. 6. Each participant must have access to and comfort with internet use, including a working email address and adequate vision or appropriate assistive devices to be able to open and read email communications and participate in an online mentor training session. 7. Each participant must demonstrate the capacity to consent to research participation. 8. Each participant must not have any known terminal diagnoses or life expectancy less than 2 years, by self-report. 9. If PLBD is alive, their cognitive or visual hallucinations have been present for 3 or more years, or between 2-3 years and caregiver actively opts for the mentor role after review of roles and responsibilities with a study team member. 2. Caregivers: 1. Participants must be 18 years of age or older. 2. participant must be English-speaking. 3. Participant must be US-dwelling. 4. Participants must be either: 1. Individuals currently cohabitating with or spending at least 10 hours weekly on caregiving for a family member diagnosed with LBD, as measured by LBCRS score = 3, OR 2. met this criterion in the past if the family member with LBD is deceased. 5. Caregiver must have access to and comfort with telephone use, including adequate hearing or appropriate assistive devices to communicate by phone 6. Caregiver must have access to and comfort with internet use, including a working email address and adequate vision or appropriate assistive devices to be able to open and read email communications and participate in an online mentor training session. 7. Caregiver must demonstrate capacity to consent to research participation. 8. Caregiver must not have any known terminal diagnoses or life expectancy less than 2 years, by self-report 9. PLBD cognitive symptom or visual hallucination onset within the past two years, OR symptoms for 2-3 years and after one-on-one explanation of mentor role and responsibilities with study team member, does not feel confident in ability to serve as a mentor, opts for the role of caregiver participant and being randomized to PERSEVERE or attention control. Exclusion Criteria: 1. Peer mentors 1. Individual is less than 18 years of age. 2. Individual is not English-speaking. 3. Individual is not US-dwelling. 4. Individual who does/did not cohabitate with or spend at least 10 hours weekly on caregiving. 5. Individual was paid for more than 50% of their caregiving responsibilities. 6. Individual does not have access to or comfort with telephone use or lacks adequate hearing or appropriate assistive devices to communicate by phone. 7. Individual does not have access to or comfort with internet use, including a working email address or adequate vision or appropriate assistive devices to be able to open and read email communications and participate in an online mentor training session. 8. Individual lacks capacity to consent to research participation. 9. PHQ-9 greater than 14, indicating severe depression. 10. PHQ-9 question 9 (suicidal ideation) greater than 1. 11. BGQ greater than 5, indicating complicated grief. 12. Individual endorses a known terminal diagnosis or life expectancy less than 2 years, by self-report. 13. PLBD cognitive symptom or visual hallucination onset less than 2 years (meeting this criterion qualifies individual as caregiver participant instead) 14. PLBD cognitive symptom or visual hallucination onset 2-3 years ago but after one-on-one explanation of mentor role and responsibilities with study team member, does not feel confident in ability to serve as a mentor; may opt for the role of caregiver participant and being randomized to PERSEVERE or attention control. 2. Caregivers: 1. Caregiver is less than 18 years of age. 2. Caregiver is not English-speaking. 3. Caregiver is not US-dwelling. 4. Caregiver's PLBD scores 0-2 on LBCRS 5. Caregiver does not cohabitate with or spend at least 10 hours weekly on caregiving. 6. Caregiver is paid for more than 50% of their caregiving responsibilities. 7. PLBD is living in a nursing facility at the time of screening. 8. Caregiver does not have access to or comfort with telephone use, or lacks adequate hearing or appropriate assistive devices to communicate by phone. 9. Caregiver does not have access to or comfort with internet use, including a working email address or adequate vision or appropriate assistive devices to be able to open and read email communications. and participate in an online mentor training session. 10. PHQ-9 greater than 14, indicating severe depression. 11. PHQ-9 question 9 (suicidal ideation) greater than 1. 12. Caregiver lacks capacity to consent to research participation. 13. Caregiver endorses a known terminal diagnosis or life expectancy less than 2 years, by self-report. 14. PLBD cognitive symptoms or visual hallucinations have been present. for less than 3 years, or between 2-3 years and caregiver actively opts for the mentor role. |
Country | Name | City | State |
---|---|---|---|
United States | Rush University Medical Center | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Rush University Medical Center | National Institute on Aging (NIA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Frequency and Duration of Mentoring Calls | Online structured survey of number and duration of calls per Mentee-Mentor dyad since last survey | Assessed at 2,4,6,8,10 and 12 weeks (Biweekly x 12 weeks) | |
Other | Study adherence of Mentors and Mentees | Proportion of mentors and mentees dyads still in communication | Assessed at Week 12 and Week 38 | |
Other | Coverage of target topics; additional topics discussed | Online structured survey with checkboxes for topics discussed, free-text response options for additional topics. | Assessed Weeks 2,4,6,8,10 and 12 weeks (Biweekly x 12 weeks) | |
Primary | Multidimensional Caregiver Strain Index (MCSI) | An 18-item validated measurement of strain of caregiving among informal caregivers. Scores range from 0-72, with higher scores indicating higher caregiver strain. | Assessed at Weeks 0,12 and 38. | |
Primary | Quality of Life in Alzheimer's Disease ( QoL-AD) | A 13-item scale for quality of life for individuals with dementia, validated for caregiver to proxy report on person with dementia's behalf. | Assessed at Weeks 0, 12 and 38. | |
Primary | Dementia Attitudes Scale (DAS) | A validated, 20-item scale measuring participants' attitudes toward dementia and individuals with dementia. Scores can range from 7-140, with higher scores indicating more positive attitudes | Assessed at Weeks 0,12 and 38 | |
Primary | LBD Knowledge Test ( LBDK) | A 12-item, multiple-choice test created by the study team to assess participants' level of knowledge of LBD, validated initially in a cohort of healthcare professionals (Hess SP et al, 2022). Calculated scores range from 0-100, with higher scores indicating a greater degree of knowledge of LBD and its effects. | Assessed at Weeks 0, 12 and 38. | |
Primary | Baseline PLBD Fall Frequency and Healthcare Utilization Questionnaire | A 19-item questionnaire, developed in 2020 by PI and study team to quantify number of falls, number of healthcare utilizations, and causes of hospital encounters for a patient for whom mentees are caring. Each item scored individually, with no summary scale or total score. | Assessed at Week- 0 (Baseline) | |
Secondary | Fortinsky Caregiver Self-Efficacy Score | A 9-item scale assessing two domains of caregiver self-efficacy: symptoms management self- efficacy ( items 1-5, score range 5-50) and community support services use self-efficacy (items 6-9, score range 4-40). Each item is scored using a visual analogue scale, 1-10. | Assessed at Weeks 0, 12 and 38. | |
Secondary | Multidimensional Scale of Perceived Social Support (MSPSS) | A 12-item Likert scale scale indicating level of perceived social support by caregivers. Developed to subjectively assess the social support of an individual. Likert scale with 1 is "Very Strongly Disagree", 4 "Neutral" and 7" Very Strongly Agree" | Assessed at Weeks 0,12 and 38. | |
Secondary | Pearlin Mastery Scale | A 7-item scale measuring the extent to which a participant sees life as being under his/her personal control vs. something that is fatalistically ruled. Score ranges from 7 to 28, with higher scores indicating greater levels of mastery | Assessed at Weeks 0,12 and 38 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03996460 -
K0706 for Patients Diagnosed With Dementia With Lewy Bodies
|
Phase 2 | |
Recruiting |
NCT04335994 -
ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing
|
N/A | |
Recruiting |
NCT02194816 -
Modifiable Variables in Parkinsonism (MVP)
|
||
Active, not recruiting |
NCT01208675 -
The Swedish BioFINDER Study
|
||
Completed |
NCT03538522 -
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
|
Phase 2 | |
Recruiting |
NCT03672448 -
The China Longitudinal Aging Study of Cognitive Impairment
|
||
Completed |
NCT01340001 -
Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies
|
N/A | |
Not yet recruiting |
NCT04760860 -
Terazosin for Dementia With Lewy Bodies
|
Phase 1/Phase 2 | |
Completed |
NCT02910102 -
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
|
Phase 2 | |
Terminated |
NCT02928445 -
Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension
|
Phase 2/Phase 3 | |
Terminated |
NCT02871427 -
Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
|
Phase 2 | |
Completed |
NCT05188105 -
Alpha tACS in Dementia With Lewy Bodies
|
N/A | |
Active, not recruiting |
NCT04167813 -
Trial of Ondansetron as a Parkinson's HAllucinations Treatment
|
Phase 2 | |
Enrolling by invitation |
NCT04954183 -
Development of an EEG Diagnostic for Alzheimer's Disease
|
||
Recruiting |
NCT05326750 -
Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases
|
N/A | |
Completed |
NCT01023672 -
"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"
|
Phase 4 | |
Completed |
NCT03907748 -
Home-based Family Caregiver-delivered Music and Reading Interventions for People With Dementia
|
N/A | |
Completed |
NCT04649164 -
Learning to PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia
|
N/A | |
Recruiting |
NCT03924414 -
Trial of Parkinson's And Zoledronic Acid
|
Phase 4 | |
Completed |
NCT05885620 -
SAMi Intervention Study to Evaluate Smartwatch Interventions in Persons With MCI and Dementia
|
N/A |